[go: up one dir, main page]

DE69305776D1 - Behandlung neurodegenerativer Krankheiten - Google Patents

Behandlung neurodegenerativer Krankheiten

Info

Publication number
DE69305776D1
DE69305776D1 DE69305776T DE69305776T DE69305776D1 DE 69305776 D1 DE69305776 D1 DE 69305776D1 DE 69305776 T DE69305776 T DE 69305776T DE 69305776 T DE69305776 T DE 69305776T DE 69305776 D1 DE69305776 D1 DE 69305776D1
Authority
DE
Germany
Prior art keywords
neurodegenerative diseases
compounds
treatment
unsaturated
certain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69305776T
Other languages
English (en)
Other versions
DE69305776T2 (de
Inventor
Patrick M Lippiello
William S Caldwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RJ Reynolds Tobacco Co
Original Assignee
RJ Reynolds Tobacco Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RJ Reynolds Tobacco Co filed Critical RJ Reynolds Tobacco Co
Publication of DE69305776D1 publication Critical patent/DE69305776D1/de
Application granted granted Critical
Publication of DE69305776T2 publication Critical patent/DE69305776T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69305776T 1992-04-10 1993-04-07 Behandlung neurodegenerativer Krankheiten Expired - Fee Related DE69305776T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86659792A 1992-04-10 1992-04-10
US08/023,940 US5276043A (en) 1992-04-10 1993-03-12 Method for treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
DE69305776D1 true DE69305776D1 (de) 1996-12-12
DE69305776T2 DE69305776T2 (de) 1997-05-15

Family

ID=26697824

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69305776T Expired - Fee Related DE69305776T2 (de) 1992-04-10 1993-04-07 Behandlung neurodegenerativer Krankheiten

Country Status (5)

Country Link
US (1) US5276043A (de)
EP (1) EP0567251B1 (de)
JP (1) JPH069397A (de)
AT (1) ATE144898T1 (de)
DE (1) DE69305776T2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231658T2 (de) 1991-03-01 2001-09-06 University Of Florida Research Foundation, Inc. Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5510355A (en) * 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5776957A (en) * 1996-11-15 1998-07-07 The University Of Kentucky Research Foundation Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states
EP1083913A4 (de) * 1998-06-05 2004-03-17 Regent Court Technologies Monoaminoxidase (mao) inhibitoren und ihre verwendung .
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6890935B2 (en) * 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US7070817B2 (en) * 2002-06-26 2006-07-04 Murali K Chada Herbal composition for treating or alleviating vascular headaches, neurological conditions and neurodegenerative diseases
WO2004103991A1 (fr) * 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. Piperidines 2-substituees, bibliotheque focalisee et composition pharmaceutique
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
WO2011119722A2 (en) * 2010-03-23 2011-09-29 Rock Creek Pharmaceuticals, Inc. Use of anatabine to treat inflammation and methods of synthesizing anatabine
US8207346B2 (en) 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
EP2701704B1 (de) * 2011-04-28 2016-04-13 RCP Development, Inc. Verfahren zur verabreichung von anatabin zur behandlung von autismusspektrumsstörungen und -anfällen
US20130048001A1 (en) * 2011-08-29 2013-02-28 Jonnie R. Williams Anatabine-Enriched Tobacco Products
KR20140124354A (ko) 2011-08-29 2014-10-24 알씨피 디벨롭먼트, 인크. 항염증 지원용 제품
WO2015164798A1 (en) 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
US10471052B2 (en) 2015-02-19 2019-11-12 Mymd Pharmaceuticals, Inc. Method of treating addictions to opioids
WO2016161051A1 (en) * 2015-03-31 2016-10-06 Srq Patent Holdings, Llc Skin care products containing isomyosmine
WO2016161055A2 (en) 2015-03-31 2016-10-06 Srq Patent Holdings, Llc Methods of treating cancers, autoimmune disorders, and other conditions associated with chronic inflammation
US11219620B2 (en) 2015-03-31 2022-01-11 MyMD Pharmaceuticals (Florida), Inc. Methods of treating sarcopenia
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870794A (en) * 1974-02-20 1975-03-11 Foundation For Behavioral Rese Treatment of certain emotional disorders with nicotine compounds
HU179164B (en) * 1979-12-14 1982-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing cycloalkyl-ethers of alkanolamines
US4442292A (en) * 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4578394A (en) * 1984-12-10 1986-03-25 Hoechst-Roussel Pharmaceuticals Incorporated Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4863930A (en) * 1986-12-19 1989-09-05 Adhikary Parimal K Use of substituted 5H-pyrido- and 5H-thiazolo(2',1':2,3)imidazo (4,5-b)indoles as cholinomimetic agents
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5015741A (en) * 1989-10-03 1991-05-14 Philip Morris Incorporated Nicotine analogs
DE69231658T2 (de) * 1991-03-01 2001-09-06 University Of Florida Research Foundation, Inc. Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
US5187169A (en) * 1992-04-10 1993-02-16 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
ATE144898T1 (de) 1996-11-15
EP0567251B1 (de) 1996-11-06
US5276043A (en) 1994-01-04
JPH069397A (ja) 1994-01-18
DE69305776T2 (de) 1997-05-15
EP0567251A1 (de) 1993-10-27

Similar Documents

Publication Publication Date Title
DE69305776D1 (de) Behandlung neurodegenerativer Krankheiten
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DK1005358T3 (da) Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse
NO961478L (no) Levobupivacaine anvendelig for kontroll av kronisk smerte
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE69300321D1 (de) Behandlung neurodegenerativer Erkrankungen.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69304843D1 (de) Methode zur Behandlung von Haarausfall
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE252387T1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
DE3582935D1 (de) Mittel zur behandlung von erkrankungen der venen und des analbereichs.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69924979D1 (de) Behandlung von chronischen schmerzen
FI950403A0 (fi) Neurosuojaavia yhdisteitä
ATE204476T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee